AIM VACCINE(06660): The immune indicators of mRNA-encapsulated herpes vaccine are significantly higher than internationally available recombinant subunit vaccine products and have been filed for clinical trials in the United States.

AIM VACCINE (06660) announced that the group is actively advancing the development of vaccine product pipelines in accordance with the established company strategy. With the advantage of mRNA technology platform, the group is rapidly advancing the research and development of mRNA vaccine series products through continuous technological innovation. The mRNA herpes vaccine has recently filed for clinical trial with the Food and Drug Administration (FDA) in the United States, marking a new progress in the group's global strategy. In preclinical animal experiments, the test results from a third-party testing unit showed that the group's mRNA herpes vaccine specific T cell immunity, specific IgG antibody titers, and Fluorescent Antibody to Membrane Antigen (FAMA) titers were significantly higher than those of the internationally marketed recombinant subunit control vaccines. Currently, there is no mRNA herpes vaccine approved for market globally, and the vaccination rate of herpes vaccine in target populations is only about 0.1%, indicating a huge potential for improvement. The global sales of GSK's herpes vaccine in 2024 are approximately $4.31 billion. According to industry consultants at Zhaoshi Consulting, it is estimated that by 2030, the market size for herpes vaccine in China will reach about 20 billion RMB, while the global market size will reach about $23.9 billion. After the product is approved for market, it will bring significant performance growth to the group. The advantages of mRNA herpes vaccine in safety and immunogenicity are expected to reshape the market landscape. As one of the first companies in China to develop mRNA vaccine products and the first domestic enterprise to obtain independent patents of mRNA technology, the group has a mature mRNA vaccine research and development system. The group has now established a complete process for the entire lifecycle of mRNA vaccine research and production, and after completing clinical trials, the industrialization of mRNA vaccine products can be quickly achieved, accelerating the commercialization process of vaccine products.